Abstract
The aim of the present study was to investigate the usefulness of multidrug resistance protein 1 (MDR1) and neuropeptide Y (NPY) levels in predicting the efficacy of levetiracetam (LEV) plus oxcarbazepine (OXC) treatment administered to children with epilepsy and to determine their prognosis. Overall, 193 children with epilepsy admitted to the hospital were enrolled and randomly divided into two groups according to different treatment methods: group A (n = 106, treated with LEV plus OXC combination) and group B (n = 87, treated with OXC only). After treatment, compared with group B, group A exhibited a remarkably higher total effective rate and a significantly lower total adverse reaction rate. Areas under the curve for MDR1 and NPY for predicting ineffective treatment were 0.867 and 0.834, whereas those for predicting epilepsy recurrence were 0.916 and 0.829, respectively. Electroencephalography abnormalities, intracranial hemorrhage, neonatal convulsion, premature delivery, and MDR1 and NPY levels were independent risk factors for poor prognosis in children with epilepsy. Serum MDR1 and NPY levels exhibited a high predictive value for early epilepsy diagnosis, treatment efficacy assessment, and prognostication in children with epilepsy treated with LEV plus OXC combination.
Keywords:
Levetiracetam; Oxcarbazepine; Children with epilepsy; Multidrug resistance protein 1; Neuropeptide Y; Efficacy
Thumbnail
Thumbnail
Thumbnail
(A) Serum MDR1 levels before and after treatment in groups A and B. (B) Serum NPY levels before and after treatment in groups A and B. Note: compared with group B after treatment, *P < 0.05.
A) Serum MDR1 levels in the effective group was significantly lower than those in the ineffective group. (B) Serum NPY levels in the effective group was significantly higher than those in the ineffective group. (C) Serum MDR1 levels for predicting efficacy. (D) Serum NPY levels for predicting efficacy. Note: *P < 0.05.
(A) Serum MDR1 levels in the stable prognosis group was significantly lower than those in the recurrent group. (B) Serum NPY levels in the stable prognosis group was significantly higher than those in the recurrent group. (C) Serum MDR1 levels for predicting treatment efficacy.(D) Serum NPY levels for predicting treatment efficacy. Note: *P < 0.05.